Indivior Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Indivior Pharmaceuticals

04/08/2026 13:01

Indivior Pharmaceuticals Inc INDV.OQ reported quarterly adjusted earnings of $1.15​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 51 cents.  The mean expectation of five analysts for the quarter was for earnings of 87 cents per share. Wall Street expected results to range from 76 cents to 97 cents per share.
Revenue rose 13.6% to $343.00 million from a year ago; analysts expected $307.55 million. 
Indivior Pharmaceuticals Inc's reported EPS for the quarter was 98 cents​.
The company reported quarterly net income of $122 million.
Indivior Pharmaceuticals Inc shares had fallen by 8.9% this quarter and gained 4.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 6.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Indivior Pharmaceuticals Inc is $48.00, about 22.1% above its last closing price of $37.37
This summary was machine generated from LSEG data August 4 at 12:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.87
1.15
Beat
Mar. 31 2026 
0.66
0.96
Beat
Dec. 31 2025 
0.67
0.82
Beat
Sep. 30 2025 
0.41
0.72
Beat